Site
Search results (6 results)
-
References | 10 Mar 2015
Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients.
-
References | 4 Nov 2015
Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.
Vollmer T, Huynh L, Kelley C, Galebach P, Signorovitch J, DiBernardo A, Sasane RNeurol Sci. 2015 Nov 4. Epub 2015 Nov 04. PMID: 26537494. Abstract -
References | 22 May 2016
Determinants of High Cost in Multiple Sclerosis Patients: A Claims and Chart Review Study.
Ke X, Navaratnam P, Sasane R, Eisenberg Lawrence DF, Friedman HS, Tulsi BB, Vollmer TCurr Med Res Opin. 2016 May 20:1-47. PMID: 27207562. Abstract -
References | 9 Sep 2016
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.
Wicks P, Rasouliyan L, Katic B, Nafees B, Flood E, Sasané RBMC Res Notes. 2016; 9(1):434. Epub 2016 Sep 07. PMID: 27604188. Abstract -
References | 29 Sep 2016
Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review.
Nazareth T, Friedman HS, Navaratnam P, Herriott DA, Ko JJ, Barr P, Sasane RBMC Neurol. 2016; 16(1):187. Epub 2016 Sep 29. PMID: 27683214. Abstract -
References | 24 Jul 2015
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.
Tauhid S, Chu R, Sasane R, Glanz BI, Neema M, Miller JR, Kim G, Signorovitch JE, Healy BC, Chitnis T, et al.J Neurol. 2015 Jul 24. Epub 2015 Jul 24. PMID: 26205635. Abstract